She had expected a sweep—predictable patrols, routine contraband. This was not routine. The lead JUQ had triangulated across a swarm of low-cost drones and pinned a small team pocketed in the cleft of two buildings. The algorithm’s confidence was soft but meaningful: probability 0.78 that they were armed and preparing to relocate.
| Patent | Priority date | Main claims | |--------|---------------|-------------| | | 15 Jan 2022 | Claims a series of fluoro‑aryl pyrimidine kinase inhibitors covering JUQ‑470, with specific substitution patterns on the aromatic ring and heterocycle. | | US2023/098765 | 3 Mar 2023 | Claims the pharmacological use of JUJ‑470 (and analogs) for treatment of FGFR‑driven and angiogenesis‑dependent cancers. | | US2024/014321 (filed 2024) | 21 Jun 2024 | Claims combination regimens of JUQ‑470 with immune checkpoint inhibitors (PD‑1/PD‑L1 antibodies). | JUQ-470